A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea
- 11 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 18 (8), 993-1006
- https://doi.org/10.1007/s00520-010-0900-3
Abstract
Our aim was to evaluate the literature for the prevalence of and interventions for oral viral infections and, based on scientific evidence, point to effective treatment protocols. Quality of life (QOL) and economic impact were assessed if available in the articles reviewed. Our search of the English literature focused on oral viral infections in cancer patients within the timeframe of 1989–2007. Review methods were standardized. Cohort studies were used to determine the weighted prevalence of oral viral infection in cancer patients. The quality of selected articles were assessed and scored with respect to sources of bias, representativeness, scale validity, and sample size. Interventional studies were utilized to determine management guidelines. Literature search included measures of QOL and economic variables. Prevalence of oral herpes simplex virus (HSV) infection in neutropenic patients was higher than in patients treated with radiotherapy for head and neck cancer (49.8% vs. 0%, respectively). In patients treated with radiochemotherapy for head and neck cancer, the prevalence of oral HSV infection increases up to 43.2% (CI, 0–100%). Prevalence of HSV infection was higher when oral ulcers existed. Information about other oral viral infections is sparse. There was a significant benefit of using acyclovir to prevent HSV oral infection (at 800 mg/day). Various dosing protocols of valacyclovir achieved prevention of HSV reactivation (500 or 1,000 mg/day). The prevalence of HSV reactivation was similar for acyclovir and valacyclovir. No information about impact on QOL and economic burden was available. Acyclovir and valacyclovir are equally effective in preventing oral HSV infection. Neutropenic patients, who were primarily treated for hematological malignancies in the studies reviewed, are at a greater risk for viral infection.Keywords
This publication has 67 references indexed in Scilit:
- Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literatureSupportive Care in Cancer, 2010
- Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low‐dose acyclovir prophylaxis and pre‐transplant diagnosis of lymphoproliferative disordersTransplant Infectious Disease, 2007
- EBV detection in HIV‐related oral plasmablastic lymphomaOral Diseases, 2007
- Epstein-Barr viral infection in extranodal lymphoma of the head and neck: correlation with prognosis and response to treatmentHistopathology, 2006
- Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositisSupportive Care in Cancer, 2006
- Antiviral prophylaxis with continuous low dose acyclovir in childhood cancer.Leukemia & Lymphoma, 2006
- Low Infectious Morbidity after Intensive Chemotherapy and Autologous Peripheral Blood Progenitor Cell Transplantation in the Outpatient Setting for Women with Breast CancerClinical Infectious Diseases, 2001
- Herpes Simplex Viremia: Report of Eight Pediatric Cases and Review of the LiteratureClinical Infectious Diseases, 1994
- Herpes simplex virus and intraoral ulcers in immunocompromised patients with haematologic malignanciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Acyclovir Prophylaxis of Herpes-Simplex-Virus InfectionsNew England Journal of Medicine, 1981